Abstract

BackgroundThe transcription factor NF-kappaB is a very interesting target molecule for the design on anti-tumor, anti-inflammatory and pro-apoptotic drugs. However, the application of the widely-used molecular docking computational method for the virtual screening of chemical libraries on NF-kappaB is not yet reported in literature. Docking studies on a dataset of 27 molecules from extracts of two different medicinal plants to NF-kappaB-p50 were performed with the purpose of developing a docking protocol fit for the target under study.ResultsWe enhanced the simple docking procedure by means of a sort of combined target- and ligand-based drug design approach. Advantages of this combination strategy, based on a similarity parameter for the identification of weak binding chemical entities, are illustrated in this work with the discovery of a new lead compound for NF-kappaB. Further biochemical analyses based on EMSA were performed and biological effects were tested on the compound exhibiting the best docking score. All experimental analysis were in fairly good agreement with molecular modeling findings.ConclusionThe results obtained sustain the concept that the docking performance is predictive of a biochemical activity. In this respect, this paper represents the first example of successfully individuation through molecular docking simulations of a promising lead compound for the inhibition of NF-kappaB-p50 biological activity and modulation of the expression of the NF-kB regulated IL8 gene.

Highlights

  • The transcription factor NF-kappaB is a very interesting target molecule for the design on anti-tumor, anti-inflammatory and pro-apoptotic drugs

  • The main aim of our molecular modelling investigations was to identify natural compounds for their ability to bind to the NF-kappaB p50 as a strategy to identify molecules exhibiting inhibitory activity on the molecular interactions of the transcription factor with its target DNA sequence. p50–p65 heterodimer is the predominant NFkappaB complex in T-cells regulating HIV-1 infection and recent studies have shown that p50 unit of NF-kappaB is the one that mainly interacts with HIV-1 LTR [1,2]

  • As shown in the 2.3 Å crystal structure, the DNA/p50 complex is formed by one DNA molecule and two p50 proteins each one consisting of two distinct domains connected by a10-residue linker

Read more

Summary

Introduction

The transcription factor NF-kappaB is a very interesting target molecule for the design on anti-tumor, anti-inflammatory and pro-apoptotic drugs. The main aim of our molecular modelling investigations was to identify natural compounds for their ability to bind to the NF-kappaB p50 as a strategy to identify molecules exhibiting inhibitory activity on the molecular interactions of the transcription factor with its target DNA sequence. Different inhibitors of the NF-kappaB/DNA interactions with a rather low binding constant (in the range of 30 μM and 500 μM) are reported in the literature [5,6,7]. Some molecular modelling studies have predicted possible binding mode of the inhibitors molecules to the DNA binding region of subunit p50, starting from the crystallographic structure of the NF-kappaB homodimer [6,7,8,9]. Minimizations were performed until the average root mean square deviation of non-hydrogen atoms reached 0.3 Å

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call